Global Transdermal Patches Market
Dublin, April 27, 2023 (GLOBE NEWSWIRE) -- The "Transdermal Patches: Global Markets" report has been added to ResearchAndMarkets.com's offering.
The global market for transdermal patches market was valued at $6.4 billion in 2021. The market is expected to grow at a compound annual growth rate (CAGR) of 5.6% to reach approximately $8.8 billion by 2027.
Growth of the global market is attributed to factors such as the growing prevalence of cancer, diabetes and other chronic diseases; and strong investment in research and development activities by key market players including GlaxoSmithKline, Hisamitsu Pharmaceutical, Johnson & Johnson, Mylan Pharmaceuticals inc. (Viatris), Novartis and Teva Pharmaceutical Industries Ltd., among others.
The increasing incidence of acute and chronic pain and rising geriatric populations with osteoporosis-related issues are the major factors likely to fuel the market for topical pain management drugs.
According to the Global Burden of Disease Study 2016, the high prominence of pain and pain-related diseases is the leading cause of disability and disease burden globally. In 2016, the burden of chronic pain increased, to a recorded 1.9 billion people with symptomatic chronic conditions.
In 2020, middle-income and low-income countries' prevalence of chronic pain in adults increased to 33%, and as high as 56% in the elderly. The increasing burden of pain; rising medical costs caused by lack of low-quality pain management; and the physical, psychological and economic losses affecting individuals and their family members have made chronic pain an important public health problem. These factors of the burden of chronic pain are likely to drive the market for transdermal patches during the forecast period.
The pain relief patches segment accounted for the highest share of the global market in 2021. The opioids segment recorded $1.2 billion in revenue in 2021 and is estimated to grow at a compound annual growth rate (CAGR) of 3.3% during the forecast period. The NSAIDs segment is likely to grow in the near future at a high rate.
The Microderm segment of the transdermal patches market is estimated to be $5.0 billion in 2022 and is growing at a CAGR of 5.0% to reach a forecast value of $6.4 billion by 2027. Greater bioavailability of active ingredients, low cost, fewer side effects and the delivery of large molecules of drugs are some of the factors likely to propel the demand of usage of Microderm patches in the near future in the pharmaceutical industry and other medicinal sectors.
122 data tables and 53 additional tables
An overview of the global transdermal patches market
Estimation of the market size and analyses of global market trends, with data from 2019-2022, with projections of compound annual growth rates (CAGRs) through 2027
Highlights of the current and future market potential and quantification of transdermal patches market based on type, design, technology, application, and region
Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast
Analysis of transdermal patches pipeline products with focus on promising pipeline molecules/ drugs in development, and coverage of technological advances, scientific discoveries, and new therapies
Detailed analysis of the regulatory framework and policies, and snapshot of transdermal drug delivery system
Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies and a relevant patent analysis
Comprehensive company profiles of the leading players of the industry, including GlaxoSmithKline, Hisamitsu Pharmaceutical, Johnson & Johnson, Mylan Pharmaceuticals inc. (Viatris), Novartis and Teva Pharmaceutical Industries Ltd.
No. of Pages
2022 - 2027
Estimated Market Value (USD) in 2022
Forecasted Market Value (USD) by 2027
Compound Annual Growth Rate
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Market Overview
3.1 Overview of Transdermal Drug Delivery Systems
3.2 Mechanism of Transdermal Drug Delivery
3.3 Advantages of Transdermal Drug Delivery
3.4 Disadvantages of Transdermal Drug Delivery
3.5 Types of Transdermal Drug Delivery Systems Based on System Types/Forms
3.5.1 Transdermal Patch
3.6 Types of Transdermal Drug Delivery Systems Based on Technology Types
3.6.1 Types of Passive Transdermal Drug Delivery Systems
3.6.2 Active Transdermal Drug Delivery Systems
3.6.3 Types of Active Transdermal Drug Delivery System
3.4 Overview of Clinical Application Areas of Transdermal Drug Delivery Technologies/Systems
3.4.1 Pain Management
3.4.2 Central Nervous System Disorders
3.4.3 Hormonal Applications
3.4.4 Smoking Cessation
3.4.5 Motion Sickness
3.4.6 Cardiovascular Diseases
3.5 Pain Management Patches
3.5.1 Prevalence of Chronic Pain
3.5.2 Trends in Pain Management Patches
Chapter 4 Market Dynamics
4.1 Market Dynamics
Chapter 5 Impact of Covid-19 on Pharma Industry
5.2 Short-Term Impact on the Pharma Industry
5.3 Long-Term Impact on the Pharma Industry
5.4 Covid-19 and Pain Management
Chapter 6 Emerging Technology in Transdermal Patches
6.1 Emerging Technology
6.1.1 Transdermal Patches and Orally Dissolving Film (Odf)
6.1.2 Nemaura Pharma Transdermal Technology
Chapter 7 Global Market for Transdermal Patches by Product Type
7.2 Hormonal Patches
7.3 Neuro Drug Patches
7.4 Nicotine Patches
7.5 Cardiac and Blood-Related Patches
7.6 Pain Relief Patches
7.6.1 Market Outlook
7.7 Other Patches
Chapter 8 Global Market for Transdermal Patches by Design
Chapter 9 Global Market for Transdermal Patches by Technology
9.1 Global Market for Transdermal Patches by Technology
Chapter 10 Global Market for Transdermal Patches by Application
10.1 Global Market for Transdermal Patches by Application
10.2 Chronic Pain
10.3 Acute Pain
10.4 Neural Diseases
10.5 Hormonal Applications
10.6 Smoking Cessation
10.7 Cardiac and Blood Diseases
10.8 Other Applications
Chapter 11 Global Market for Transdermal Patches by Region
Chapter 12 Competitive Landscape
12.1 Global Analysis of Company Shares
Chapter 13 Company Profiles
Amneal Pharmaceuticals, Inc.
Bausch Health Companies Inc.
Bayer Healthcare Pharmaceuticals
Endo Pharmaceuticals Inc.
Hisamitsu Pharmaceutical Co. Inc.
Icure Pharma Inc.
Johnson & Johnson
Lavipharm S. A.
Luye Pharma Group Ltd.
Perrigo Company plc
Purdue Pharma L.P.
Sparsha Pharma International Pvt. Ltd.
Teva Pharmaceutical Industries Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/crw21z
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900